Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck/Ariad Form Billion-Dollar Collaboration To Develop mTOR Inhibitor For Cancers

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s commitment to using biomarkers, bioinformatics and diagnostics in cancer drug development was key to the deal, Ariad CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap

With positive signs for its stable of cancer drugs, including an imminent filing for the sarcoma candidate ridaforolimus, Ariad Pharmaceuticals Inc. is nearing the turning point from a development to a commercial company.

Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap

With positive signs for its stable of cancer drugs, including an imminent filing for the sarcoma candidate ridaforolimus, Ariad Pharmaceuticals Inc. is nearing the turning point from a development to a commercial company.

Ariad Opts-in To Co-Promote mTOR With Merck

The biotech takes advantage of the Big Pharma's financial wherewithal and regulatory/market expertise to build out its own commercial infrastructure.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel